Novocure’s positive phase 3 results boost pancreatic cancer treatment prospects. Read why NVCR stock is worth watching with ...

On Monday, NovoCure Ltd (NASDAQ:NVCR) and Zai Lab Limited (NASDAQ:ZLAB) revealed topline data from the Phase 3 PANOVA-3 trial ...

Shares of Novocure Ltd. skyrocketed over 55% on Monday afternoon, reaching levels last seen in August 2023, as the company ...

StudyFinds' Dr. Faith Coleman speaks with the doctor testing a new vitamin C treatment that may double the survival time of ...

Novocure (NASDAQ:NVCR) has met the primary endpoint of overall survival in a late-stage trial evaluating the use of its Tumor ...

Novocure’s TTFields therapy combined with chemo improved overall survival by 16.2 months compared to 14.16 months with chemo ...

Novocure shares jumped 26% in premarket trading following trial results of a therapy for pancreatic cancer. Shares were trading around $25.22. The stock is up 34% on the year.

Novocure has cleared a phase 3 clinical study in pancreatic cancer, showing its tumor-treating electric fields could help ...

Novocure this week announced positive topline results from its Phase 3 trial of its Tumor Treating Fields for pancreatic cancer.

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer ...

Novocure (NVCR) announced that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant ...